Elisabeth Leibundgut-Oppliger

Bern, BE 3008, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Higher Age (≥60 Years) Increases the Risk for Adverse Events during Autologous Hematopoietic Stem Cell Transplantation.

Higher Age (≥60 Years) Increases the Risk for Adverse Events during Autologous Hematopoietic Stem Cell Transplantation.

Journal: Cancers

Published: February 03, 2023

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.

Standardization of molecular monitoring of CML: results and recommendations from the European treatment and outcome study.

Journal: Leukemia

Published: March 05, 2022

Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias.

Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias.

Journal: BMC medical genomics

Published: October 20, 2021

Targeting Telomere Biology in Acute Lymphoblastic Leukemia.

Targeting Telomere Biology in Acute Lymphoblastic Leukemia.

Journal: International journal of molecular sciences

Published: April 28, 2021

Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.

Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: February 22, 2021

Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat.

Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat.

Journal: Haematologica

Published: March 23, 2020

Excellent outcome after consolidation with autologous transplantation in patients with core binding factor acute myeloid leukemia.

Excellent outcome after consolidation with autologous transplantation in patients with core binding factor acute myeloid leukemia.

Journal: Bone marrow transplantation

Published: July 06, 2019

Imetelstat inhibits growth of megakaryocyte colony-forming units from patients with essential thrombocythemia.

Imetelstat inhibits growth of megakaryocyte colony-forming units from patients with essential thrombocythemia.

Journal: Blood advances

Published: March 17, 2019

International external quality assurance of JAK2 V617F quantification.

International external quality assurance of JAK2 V617F quantification.

Journal: Annals of hematology

Published: November 11, 2018

Coincidence of 5q deletion and the JAK2V617F mutation: report of two patients with overlapping myelodysplastic and myeloproliferative features and review of the literature.

Coincidence of 5q deletion and the JAK2V617F mutation: report of two patients with overlapping myelodysplastic and myeloproliferative features and review of the literature.

Journal: Leukemia & lymphoma

Published: January 04, 2018

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

Journal: Leukemia

Published: November 08, 2017

Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement.

Response to Tyrosine Kinase Inhibitors in Myeloproliferative Neoplasia with 8p11 Translocation and CEP110-FGFR1 Rearrangement.

Journal: The oncologist

Published: September 15, 2016

Showing 1-12 of 20

Last Updated: 09/26/2026